4 March 2020

AMRA Medical Present Sarcopenia Research at ICFSR 2020 in France

AMRA Medical Present Sarcopenia Research at ICFSR 2020 in France

LINKÖPING, Sweden; March 4, 2020  ICFSR – International Conference on Frailty and Sarcopenia Research – brings together clinical, academic and industry leaders to present and discuss the latest preclinical and clinical research on frailty and sarcopenia.

AMRA will present their findings from two recent studies on sarcopenia and adverse muscle composition as an oral and poster presentation at the upcoming ICFSR in Toulouse, France March 11-13.

Sarcopenia is associated with several diseases; hospitalization; and mortality, but is underdiagnosed in patients with obesity due to the current sarcopenia definitions being BMI-dependent, where the relationship between body size and muscle mass has not been properly adjusted for1. AMRA quantified fat-free muscle volume and muscle fat infiltration of 9612 individuals using the AMRA® Researcher – a rapid MRI protocol and automated image analysis – to assess the prevalence of low functional performance and metabolic comorbidity in individuals with obesity. They found that among participants with obesity, 17.2% had adverse muscle composition, which was further associated with low functional performance (p<0.05). Additionally, in participants with obesity and adverse muscle composition, prevalence of coronary heart disease and type II diabetes was >2 times higher compared to those without adverse muscle composition.

In a second study, AMRA scientists collaborated with Linköping University’s Dr. Ainhoa Indurain to apply the concept of adverse muscle composition in patients on hemodialysis – sarcopenia prevalence is high among patients undergoing hemodialysis, ranging from 20%-30%2 – and revealed the ability of AMRA’s technique to reflect comorbidity and predict mortality in a clinical context. The MRI-based body composition assessment could not only reflect comorbidity but also effectively predict survival in patients on hemodialysis, the combined assessment including both muscle volume and muscle fat infiltration seems to improve the predictive performance.

AMRA Medical will present this research at ICFSR in the hope that clinical scientists and researchers engage with the AMRA team for future collaborations.

Learn more about AMRA Medical’s technology, research and opportunities for collaboration by attending the presentations and talking with the AMRA team. 

Visit Us at ICFSR Booth No. 7
Toulouse, France March 11-13


Oral Presentation – Presented by Jennifer Linge, MSc
Adverse Muscle Composition within Obesity is Associated with Low Functional Performance and Increased Comorbidity – Results from the Large UK Biobank Imaging Study 
Location: Conference 27
Date & Time: Thursday, March 12 at 16:45-17.00

Poster Presentation – Presented by Ainhoa Indurain, MD
A Combined MRI Measurement of Muscle Volume and Muscle Fat Infiltration Predicts Survival in Hemodialysis.
Date: Thursday, March 12


1.    Linge, Jennifer et al. “On the Definition of Sarcopenia in the Presence of Aging and Obesity – Initial Results from UK Biobank.” J Gerontol A Biol Sci Med Sci 2019 Oct 23. pii: glz229. doi: 10.1093/gerona/glz229.

2.    Mori, Katsuhito et al. “Impact of diabetes on sarcopenia and mortality in patients undergoing hemodialysis.” BMC nephrology vol. 20,1 105. 28 Mar. 2019, doi:10.1186/s12882-019-1271-8

AMRA is a ground-breaking international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, as well as contextual disease insights – all from a single, rapid, whole-body MRI. AMRA was founded in 2010 as a spin-off of Linköping University, Sweden, with the aim to support transformative care and vital decision-making from clinical research to health and wellness.


Marie Börjesson
Senior Director, Brand & Marketing


Latest News


Meet Us Here